Article Text
Statistics from Altmetric.com
We thank Murray et al for their interest and complementary comments regarding the LENT score (pleural fluid lactate dehydrogenase, Eastern Cooperative Oncology Group (ECOG) performance score (PS), neutrophil-to-lymphocyte ratio and tumour type).1 We are pleased they felt it would be a beneficial addition to multidisciplinary team discussions.
We agree with their observation that the survival differences between cell types may reflect different stages of disease at presentation with malignant pleural effusion (MPE) or the availability of subsequent effective therapies for some of the underlying tumour types. However, when designing the LENT score we chose to use the cell types themselves rather than …
Footnotes
Contributors AOC, BCK and NAM coauthored this response letter.
Competing interests None.
Ethics approval Local ethics committees in Bristol, Perth and Amsterdam.
Provenance and peer review Not commissioned; internally peer reviewed.